Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

Market Cap	381.02B
Revenue (ttm)	29.19B
Net Income (ttm)	6.84B
Shares Out	6.63B
EPS (ttm)	1.09
PE Ratio	52.40
Forward PE	45.83
Dividend	0.20 (0.37%)
Ex-Dividend Date	May 23, 2025

Volume	115,821,169
Average Volume	44,569,033
Open	53.40
Previous Close	53.40
Day's Range	53.02 - 57.94
52-Week Range	38.01 - 57.53
Beta	0.36
RSI	69.96
Earnings Date	Aug 21, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600276

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.